Don S. Dizon will join Tufts Medicine in June 2025 as the system chief of hematology-oncology for the cancer service line. He will be proposed as the Jane F. Desforges endowed Professor in Hematology-Oncology at Tufts University School of Medicine.
Karen PollokTim LautenschlaegerJiang BianKaren Pollok was named associate director of basic science research and Tim Lautenschlaeger was named associate director of clinical research at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center. Jiang Bian also recently began as chief research information officer.
Cancer Research UK and partners on March 31 committed £5.5 million in funding to form a research team tasked with making personalized medicine a reality for people with colorectal cancer. The initiative is designed to unite research expertise and solve unanswered questions about the disease.
University Hospitals Cleveland Medical Center has announced a collaboration with global healthcare AI company Qure.ai to deploy chest X-ray AI supporting earlier identification of lung cancers.
The University of Texas MD Anderson Cancer Center on March 31 broke ground on a new 470,000-square-foot facility in Sugar Land, bringing a range of cancer services closer to those living in Southwest Houston and the surrounding areas.
Although lung cancer screening is recommended in the U.S. for certain individuals with a history of smoking, only 18% of eligible individuals in the U.S. get screened.
Researchers have identified a “master regulator” gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.
Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice, according to results of a study published in Cancer Research, a journal of the American Association for Cancer Research.
A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
FDA approved AstraZeneca’s durvalumab (Imfinzi) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer.
